FGFR3 Antibody (136812)

Recombinant Mouse FGF R3 (IIIc) Fc Chimera (Catalog # 710-MF) inhibits Recom­binant Human FGF acidic (Catalog # 232‑FA) induced proliferation in the NR6R‑3T3 mouse fibroblast cell line in a dose-dependent manner (orange line). Inhibition of Recom­binant Human FGF acidic (0.3 ng/mL) activity elicited by Recom­binant Mouse FGF R3 (IIIc) Fc Chimera (12 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse FGF R3 Mono­clonal Antibody (Catalog # MAB710). The ND50 is typically 3-12 µg/mL in the presence of heparin (10 µg/mL).

• Reactivity: Mu
• Applications: B/N
• Clone: 136812
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

FGFR3 Antibody (136812) Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse FGF R3
  Glu21-Tyr369 (Asn310Ile, Ala354 del) (predicted)
  Accession # NP_001156689
• Specificity: Detects mouse FGF R3 in direct ELISAs. In direct ELISAs, 100% cross-reactivity with the (IIIb) and (IIIc) isoforms of recombinant human FGF R3 is observed. Neutralizes the bioactivity of mouse FGF R3. Functions equally as well in the neutralization of recombinant mouse (rm) FGF R3 alpha (IIIb) and rmFGF R3 alpha (IIIc).
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: FGFR3
• Purity: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 3-12 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Purity: Protein A or G purified from hybridoma culture supernatant
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGFR3 Antibody (136812)

• CD333
• CEK
• EC 2.7.10
• FGF R3
• FGFR3
• fibroblast growth factor receptor 3
• HSFGFR3EX
• JTK4
• JTK4thanatophoric dwarfism

Background

Fibroblast growth factors (FGFs) comprise a family of at least eighteen structurally related proteins that are involved in a multitude of physiological and pathological cellular processes, including cell growth, differentiation, angiogenesis, wound healing and tumorgenesis. The biological activities of the FGFs are mediated by a family of type I transmembrane tyrosine kinases which undergo dimerization and autophosphorylation after ligand binding. Four distinct genes encoding closely related FGF receptors, FGF R1‑4, are known. All four genes for FGF Rs encode proteins with an N‑terminal signal peptide, three immunoglobulin (Ig)‑like domains, an acid‑box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine‑kinase domain. Multiple forms of FGF R1‑3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the alpha  isoform, or only IgII and IgIII, referred to as the beta  isoform. Only the alpha  isoform has been identified for FGF R3 and FGF R4. Additional splicing events for FGF R1‑3, involving the C‑terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF receptors with alternative IgIII domains (IIIb and IIIc). A IIIa isoform which is a secreted FGF binding protein containing only the N‑terminal half of the IgIII domain plus some intron sequences has also been reported for FGF R1. Mutations in FGF R1‑3 have been found in patients with birth defects involving craniosynostosis. The complex patterns of expression of these receptors as well as the specificity of their interactions with the various FGF ligand family members are being investigated.

1. Galzie, Z. et al. (1997) Biochem. Cell Biol. 75:669.
2. Burke, D. et al. (1998) Trends Biochem. Sci. 23:59.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FGFR3 Antibody (MAB710)(2)

Publications using MAB710

• Yue Zhang Neuronal mTORC1 is required for maintaining the nonreactive state of astrocytes J. Biol. Chem, 2016;0(0):. 2016 [PMID: 27895121] (Neutralization, Mouse)
• Shin JW, Min M, Larrieu-Lahargue F, Canron X, Kunstfeld R, Nguyen L, Henderson JE, Bikfalvi A, Detmar M, Hong YK Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol. Biol. Cell, 2005;17(2):576-84. 2005 [PMID: 16291864] (IHC-Fr, Mouse)

Bioinformatics

• Gene Symbol: FGFR3
• Uniprot:
  • NP_001156689()